Publications / Presentations

Neuropsychiatry / Neurology

Publications

  • Journal of Neurology and Neuromedicine 2018, 3(5):39-50 (Invited Review).

Brilaroxazine (RP5063) Clinical Experience in Schizophrenia: A New Option to Address Unmet Needs.

Laxminarayan Bhat, Marc Cantillon, and Robert Ings

  • European Journal of Drug Metabolism and Pharmacokinetics 2018, 43:573-585.

A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.

Marc Cantillon, Robert Ings, Arul Prakash, Laxminarayan Bhat

  • Clinical and Translational Science 2018, 11:387-396.

Initial clinical experience of RP5063 following single doses in normal healthy volunteers and multiple doses in patients with stable schizophrenia.

Marc Cantillon, Robert Ings, and Laxminarayan Bhat

  • Clinical and Translational Science 2018, 11:378-386.

Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients.

Marc Cantillon, Robert Ings, and Laxminarayan Bhat

  • Schizophrenia Research 2017, 189: 126-133.

Dopamine Serotonin Stabilizer RP5063: A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Safety and Efficacy in Exacerbation of Schizophrenia or Schizoaffective Disorder.

Marc Cantillon, Arulprakash R, Ajay Alexander, Robert Ings, Dennis Sweitzer, Laxminarayan Bhat

  • Behavioral Brain Research 2017, 332: 180-199.

RP5063, an atypical antipsychotic drug with a novel mechanism of action, improves cognition and psychosis in mouse models of schizophrenia.

Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, Eric Michael, Laxminaryan Bhat, Marc Cantillon, Herbert Y. Meltzer

 

Presentations

  • Society for Neuroscience Annual Meeting, Chicago, USA. October 17-21, 2015

RP5063 reverses and prevents subchronic phencyclidine-induced declarative memory deficits and increases cortical dopamine in C57BL/6J mice.

Kwon S. et al.

  • New Clinical Drug Evaluation Unit (NCDEU) Conference, Hollywood, Florida, USA. May 29, 2013.

RP5063 safety and efficacy in schizophrenia and schizoaffective disorder.

Cantillon M. et al.

  • New Clinical Drug Evaluation Unit (NCDEU) Conference, Phoenix, Arizona, USA. May 30, 2012.

RP5063 safety, pharmacokinetics and pharmacodynamics in schizophrenia.

Cantillon M. et al.

 

 

Vascular / Pulmonary Diseases

Publications

  • Journal of Genetic Syndromes & Gene Therapy 2018, 9:43.

Pulmonary arterial hypertension and pulmonary fibrosis: treatments, unmet needs and future directions.

Laxminarayan Bhat.

  • Journal of Genetic Syndromes & Gene Therapy 2018, 9:36.

Serotonergic targets in the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).

Laxminarayan Bhat.

  • European J Pharmacology 2018, 827:159-166.

Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in the monocrotaline-induced pulmonary arterial hypertension rat model.

Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.

  • Biomedical Advances in Cardiovascular Disease 2018 Feb (Invited Synopsis)

RP5063 is effective in sugen-hypoxia-induced pulmonary arterial hypertension in rats.

Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.

  • Journal of Rare Disease Research & Treatment 2017, 2(5): 5-12 (Invited Review)

A closure look at the preclinical experience of RP5063 in pulmonary arterial hypertension (PAH).

Laxminarayan Bhat and Dany Salvail.

  • European J Pharmacology 2017, 810: 83-91.

RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-induced pulmonary arterial hypertension in rats.

Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.

  • European J Pharmacology 2017, 810: 92-99.

RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.

Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.

 

Presentations

  • American Thoracic Society (ATS) International Conference, Washington DC, USA. May 19-24, 2017.

RP5063 mitigates the developments and severity of sugen-hypoxia induced pulmonary arterial hypertension in rats.

Bhat L. et al.

  • American Thoracic Society (ATS) International Conference, San Francisco, USA. May 13-18, 2016

RP5063 prevents moncrotaline-induced pulmonary arterial hypertension in rats.

Bhat L. et al.

TOP